This page shows the latest Exjade news and features for those working in and with pharma, biotech and healthcare.
The committee also recommended a new generic from Mylan of Novartis’ Exjade (deferasirox), which is used to treat chronic iron overload due to blood transfusions in patients with beta thalassaemia, ... Exjade made sales of more than $1bn last year. The
In 2015, Novartis paid $390m to settle claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.
Last November, the company settled civil claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.
Meanwhile, supportive therapies are also available, notably Novartis' Exjade (deferasirox) which was approved in the EU last year to manage iron overload in thalassaemia.
For the first time, Exjade will be available to thalassemia patients who are not regularly transfused but still suffer from the life-altering effects of excess iron," he added. ... Approval in thalassaemia adds to the peak sales potential for Exjade and
Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...